← All trials
NCT00003140
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 1998
- Primary completion
- Oct 1, 2003
- Completion date
- Oct 1, 2003
- First posted
- —
- Last posted
- —
- Enrollment
- 5187
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- Free University of BrusselsStudy chair
- Mayo ClinicStudy chair
- John Wayne Cancer InstituteStudy chair
- University of VermontStudy chair
- University of BernStudy chair
- Harvard UniversityStudy chair
- Fairfax Northern Virginia Hematology Oncology, PC - FairfaxStudy chair
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- International Breast Cancer Study GroupCollaborator
- Eastern Cooperative Oncology GroupCollaborator
- Southwest Oncology GroupCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- Cancer and Leukemia Group B (CALGB)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.